{
  "pmid": "80001003",
  "title": "Network Meta-Analysis of Biologic Therapies for Moderate-to-Severe Plaque Psoriasis",
  "year": 2024,
  "population": {
    "description": "Adults with moderate-to-severe plaque psoriasis defined as PASI score >= 10 and BSA >= 10%",
    "sample_size": 28500,
    "inclusion_criteria": {
      "age_range": {"min_age": 18, "max_age": 99},
      "primary_diagnosis": "plaque psoriasis",
      "comorbidity_requirements": []
    },
    "exclusion_criteria": {
      "contraindications": ["active tuberculosis", "severe immunosuppression"],
      "prior_treatments_excluded": []
    }
  },
  "endpoints": [
    {
      "endpoint_phrase": "PASI 90 response at 16 weeks",
      "endpoint_classification": "primary",
      "point_estimate": 3.2,
      "confidence_interval": {"lower": 2.6, "upper": 3.9},
      "p_value": 0.00001,
      "statistical_method_description": "Bayesian network meta-analysis with random effects and informative priors",
      "subgroup_analyses": [
        {
          "subgroup_definition": "biologic-naive patients",
          "point_estimate": 3.8,
          "confidence_interval": {"lower": 3.0, "upper": 4.8}
        },
        {
          "subgroup_definition": "anti-TNF experienced patients",
          "point_estimate": 2.1,
          "confidence_interval": {"lower": 1.5, "upper": 2.9}
        },
        {
          "subgroup_definition": "patients with psoriatic arthritis",
          "point_estimate": 2.8,
          "confidence_interval": {"lower": 2.0, "upper": 3.9}
        }
      ]
    },
    {
      "endpoint_phrase": "PASI 100 response at 16 weeks",
      "endpoint_classification": "secondary",
      "point_estimate": 2.1,
      "confidence_interval": {"lower": 1.6, "upper": 2.8},
      "p_value": 0.0001,
      "statistical_method_description": "Bayesian network meta-analysis with random effects",
      "subgroup_analyses": []
    }
  ],
  "adverse_events": [
    {
      "event": "upper respiratory infection",
      "severity": "mild",
      "mechanism_of_action": "immunosuppression via IL-17A inhibition",
      "incidence_rate": 0.15,
      "time_to_onset_days": {"median": 60, "range_min": 14, "range_max": 365}
    },
    {
      "event": "injection site reaction",
      "severity": "mild",
      "mechanism_of_action": null,
      "incidence_rate": 0.08,
      "time_to_onset_days": {"median": 1, "range_min": 1, "range_max": 3}
    }
  ],
  "study_design": "meta-analysis",
  "funding_source": null,
  "registration_number": "CRD42024567890",
  "limitations": "Heterogeneity across included trials in patient populations and concomitant therapies"
}